Senior Director, Corporate Controller Hisayoshi Kashima PLAY LIST from the beginning Q1 FY2018 (April 1 to June 30, 2018) Conference Call Disclaimer Regarding Forward-looking Statements Financial Results for Q1 FY2018 Financial Results for Q1 FY2018 (Core Basis) Revenue of Major Products in Japan Revenue of Major Products in North America & China Segment Information (Core Basis) Financial Results for Q1 FY2018 (Full Basis) Financial Forecasts for FY2018 Financial Forecasts for FY2018 (Core Basis) Research and Development Development Pipeline (as of July 2018) Clinical Development Status (Major Changes since May 11, 2018) Dasotraline: BED Phase 3 Study Results (SEP360-321 study) Alvocidib: Phase 2 Study Design & NDA Submission Target for AML Activities in FY2018: Clinical Development Status Appendices Adjustments to Core Operating Profit Product Launch Target (as of July 2018) Regenerative Medicine/Cell Therapy Business Plan (as of July 2018) Psychiatry & Neurology: Apomorphine (Phase 3 study) Oncology: Alvocidib (r/r AML Zella 201 study) Oncology: Napabucasin (Pancreatic cancer 118 study) @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Back Next